Pathogenesis of nonketotic hyperosmolar diabetic coma.
Two concepts are advanced to explain some fo the puzzling biochemical features found in nonketotic hyperosmolar diabetic coma. It is firstly suggested that an insulinised liver (reflecting residual beta-cell secretory activity) coexists with a diabetic periphery, thereby inactivating intrahepatic oxidation of incoming free fatty acids, which are directed largly along nonketogenic metabolic pathways such as triglyceride synthesis. This could account for the lack of hyperketonaemia. Secondly, it is hypothesised that within the liver enhanced neoglucogenesis occurs, due to the prevailing portal-vein into ratio of glucagon to insulin, and is mainly responsible for the development of massive hyperglycaemia.
D000818:Animals; D003920:Diabetes Mellitus / Q000378:metabolism* / Q000503:physiopathology; D003926:Diabetic Coma / Q000209:etiology*; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D005934:Glucagon / Q000502:physiology; D006003:Glycogen / Q000378:metabolism; D006801:Humans; D006943:Hyperglycemia / Q000209:etiology; D007328:Insulin / Q000097:blood / Q000378:metabolism; D007515:Islets of Langerhans / Q000503:physiopathology; D008099:Liver / Q000378:metabolism / Q000503:physiopathology; D008657:Metabolic Clearance Rate; D009994:Osmolar Concentration; D010084:Oxidation-Reduction; D051381:Rats; D014280:Triglycerides / Q000378:metabolism
D005230:Fatty Acids, Nonesterified; D007328:Insulin; D014280:Triglycerides; D006003:Glycogen; D005934:Glucagon